High Dose Nimodipine Treatment Adjunct - 1

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000332
First received: September 20, 1999
Last updated: June 23, 2005
Last verified: December 2002
  Purpose

The purpose of this study is to determine if nimodipine is more effective than placebo in reducing stimulated craving for cocaine in cocaine dependent individuals denied access to cocaine in inpatient unit.


Condition Intervention Phase
Cocaine-Related Disorders
Drug: Nimodipine
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: High Dose Nimodipine Pharmacotherapy Adjunct

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Stimulated and non-stimulated craving
  • Stimulated and non-stimulated withdrawal
  • Anxiety, depression
  • Heart rate

Estimated Enrollment: 0
  Eligibility

Ages Eligible for Study:   22 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000332

Locations
United States, District of Columbia
Washington DC VA
Washington, District of Columbia, United States, 20422
Sponsors and Collaborators
Investigators
Principal Investigator: Steven Deutsch, M.D. Washington DC VA
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000332     History of Changes
Other Study ID Numbers: NIDA-3-0009-1, Y01-3-0009-1
Study First Received: September 20, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Substance-Related Disorders
Nimodipine
Antihypertensive Agents
Calcium Channel Blockers
Cardiovascular Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Vasodilator Agents

ClinicalTrials.gov processed this record on October 21, 2014